Data Requirements for Patenting Biotech/Pharma Inventions in China and the EU

In Webinars

1 July, 2020

This interactive webinar considers the filing and post-filing data requirements for biotechnology and pharmaceutical-related inventions in China and the EU. Xiaofan Chen, Hai Liu and Helle Friis Svenstrup from AWA’s Asian and European offices explain the minimum data requirements during filing and also the criteria for supplementary data. They also consider the use of post-grant data as evidence during invalidation proceedings. Understanding the differences between the European and Chinese regimes is essential for applicants to be successful.

 

 

 

You may also be interested in:

Amendments to Hong Kong’s Trade Marks Ordinance paves the way for Madrid Protocol

The Trade Marks (Amendment) Ordinance 2020 was gazetted on June 19, 2020. While the Amendment does not introduce any

Read more...

Court decisions highlight challenges using copyright to protect designs in Denmark

Two eagerly-awaited decisions from the Danish courts serve as a reminder that registered design rights offer greater protection over

Read more...

How to fast track patent applications in China through prioritised patent examination

Xiaofan Chen from AWA Asia’s patent team in Beijing looks at how applicants can streamline the examination of certain

Read more...

Mobile Sliding Menu